AU2002362005A1 - Methods and apparatus for blood typing with optical bio-discs - Google Patents
Methods and apparatus for blood typing with optical bio-discs Download PDFInfo
- Publication number
- AU2002362005A1 AU2002362005A1 AU2002362005A AU2002362005A AU2002362005A1 AU 2002362005 A1 AU2002362005 A1 AU 2002362005A1 AU 2002362005 A AU2002362005 A AU 2002362005A AU 2002362005 A AU2002362005 A AU 2002362005A AU 2002362005 A1 AU2002362005 A1 AU 2002362005A1
- Authority
- AU
- Australia
- Prior art keywords
- disc
- cells
- capture
- chamber
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003287 optical effect Effects 0.000 title claims description 218
- 238000000034 method Methods 0.000 title claims description 150
- 238000009582 blood typing Methods 0.000 title claims description 56
- 210000004027 cell Anatomy 0.000 claims description 390
- 239000008280 blood Substances 0.000 claims description 266
- 210000004369 blood Anatomy 0.000 claims description 261
- 210000002966 serum Anatomy 0.000 claims description 127
- 238000002156 mixing Methods 0.000 claims description 121
- 239000000427 antigen Substances 0.000 claims description 119
- 102000036639 antigens Human genes 0.000 claims description 112
- 108091007433 antigens Proteins 0.000 claims description 112
- 238000004458 analytical method Methods 0.000 claims description 98
- 238000003556 assay Methods 0.000 claims description 85
- 210000003743 erythrocyte Anatomy 0.000 claims description 84
- 239000000758 substrate Substances 0.000 claims description 77
- 239000003795 chemical substances by application Substances 0.000 claims description 76
- 238000012360 testing method Methods 0.000 claims description 73
- 239000003153 chemical reaction reagent Substances 0.000 claims description 68
- 238000000926 separation method Methods 0.000 claims description 62
- 238000009739 binding Methods 0.000 claims description 54
- 230000027455 binding Effects 0.000 claims description 53
- 238000009987 spinning Methods 0.000 claims description 43
- 230000004520 agglutination Effects 0.000 claims description 42
- 230000005670 electromagnetic radiation Effects 0.000 claims description 36
- 239000011159 matrix material Substances 0.000 claims description 36
- 239000012530 fluid Substances 0.000 claims description 23
- 238000004891 communication Methods 0.000 claims description 21
- 230000006854 communication Effects 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 102000004856 Lectins Human genes 0.000 claims description 13
- 108090001090 Lectins Proteins 0.000 claims description 13
- 239000002523 lectin Substances 0.000 claims description 13
- 230000033001 locomotion Effects 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 239000013641 positive control Substances 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 210000000601 blood cell Anatomy 0.000 claims description 7
- 239000012491 analyte Substances 0.000 claims description 6
- 230000009830 antibody antigen interaction Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000006395 Globulins Human genes 0.000 claims description 5
- 108010044091 Globulins Proteins 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims 3
- 206010049190 Red blood cell agglutination Diseases 0.000 claims 2
- 238000000151 deposition Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 description 150
- 239000000523 sample Substances 0.000 description 115
- 238000001514 detection method Methods 0.000 description 43
- 230000002441 reversible effect Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000010931 gold Substances 0.000 description 26
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 25
- 229910052737 gold Inorganic materials 0.000 description 25
- 108010090804 Streptavidin Proteins 0.000 description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 239000000853 adhesive Substances 0.000 description 16
- 230000001070 adhesive effect Effects 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- 238000012545 processing Methods 0.000 description 14
- 239000004033 plastic Substances 0.000 description 13
- 229920003023 plastic Polymers 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 239000011616 biotin Substances 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 9
- 235000020958 biotin Nutrition 0.000 description 9
- 239000004417 polycarbonate Substances 0.000 description 9
- 229920000515 polycarbonate Polymers 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000000873 masking effect Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000004971 Cross linker Substances 0.000 description 5
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000001459 lithography Methods 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000012984 biological imaging Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 235000003869 genetically modified organism Nutrition 0.000 description 2
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 2
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- -1 polydextran Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100180423 Homo sapiens KRT31 gene Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102100023131 Keratin, type I cuticular Ha1 Human genes 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000009489 vacuum treatment Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/988,850 US7087203B2 (en) | 2000-11-17 | 2001-11-19 | Methods and apparatus for blood typing with optical bio-disc |
| US09/988,850 | 2001-11-19 | ||
| US35301402P | 2002-01-29 | 2002-01-29 | |
| US60/353,014 | 2002-01-29 | ||
| US35377302P | 2002-01-31 | 2002-01-31 | |
| US60/353,773 | 2002-01-31 | ||
| US37556802P | 2002-04-25 | 2002-04-25 | |
| US60/375,568 | 2002-04-25 | ||
| US37904502P | 2002-05-09 | 2002-05-09 | |
| US60/379,045 | 2002-05-09 | ||
| PCT/US2002/036792 WO2003043403A2 (fr) | 2001-11-19 | 2002-11-15 | Methode et appareil de typage sanguin a l'aide de bio-disques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002362005A1 true AU2002362005A1 (en) | 2003-06-10 |
Family
ID=27541241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002362005A Abandoned AU2002362005A1 (en) | 2001-11-19 | 2002-11-15 | Methods and apparatus for blood typing with optical bio-discs |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1451589A4 (fr) |
| JP (1) | JP2005509865A (fr) |
| AU (1) | AU2002362005A1 (fr) |
| CA (1) | CA2467740A1 (fr) |
| WO (1) | WO2003043403A2 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054405A1 (en) * | 2003-10-23 | 2007-03-08 | Ortho-Clinical Diagnostics, Inc. | Patient sample classification based upon low angle light scattering |
| JP4884981B2 (ja) * | 2003-12-22 | 2012-02-29 | マイクロ・タイピング・システムズ・インコーポレイテッド | 血液バンク診断試験に要する時間の短縮 |
| SE0400403D0 (sv) * | 2004-02-20 | 2004-02-20 | Karl Andersson | Method and device for the characterization of interactions between different species |
| EP1775592A4 (fr) * | 2004-07-12 | 2012-05-09 | Arkray Inc | Analyseur, méthode pour spécifier la ...réaction dans l"analyseur, appareil analytique |
| GB0506183D0 (en) * | 2005-03-24 | 2005-05-04 | Univ Edinburgh | Antigen detection |
| JP2009030997A (ja) * | 2007-07-24 | 2009-02-12 | Olympus Corp | タイプ＆スクリーニングのための血液型判定キット及び該キットを用いる血液型判定装置 |
| JP2014525570A (ja) * | 2011-08-30 | 2014-09-29 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | Ａｂｏ抗体の検出および特性解析の方法およびシステム |
| JP6466193B2 (ja) * | 2015-02-16 | 2019-02-06 | 国立研究開発法人産業技術総合研究所 | 赤血球凝集検出装置および検出方法 |
| US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
| US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
| US20170066839A1 (en) | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
| CN110146711B (zh) * | 2019-04-12 | 2022-09-16 | 杭州电子科技大学 | 一种全自动血型检验装置及其血型检验方法 |
| CN110339876B (zh) * | 2019-06-27 | 2021-04-30 | 昆明理工大学 | 一种基于液滴寄存的肿瘤细胞筛查微流控装置及筛查方法 |
| CN114563583B (zh) * | 2022-04-24 | 2022-07-22 | 天津德祥生物技术有限公司 | 一种高通量微反应血型正定检测装置 |
| CN116196991B (zh) * | 2023-04-11 | 2024-01-19 | 江苏泽亚生物技术有限公司 | 一种微流控血型抗原鉴定芯片 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2535058B1 (fr) * | 1982-10-21 | 1987-08-21 | Materiel Biomedical | Dispositif pour la detection et la quantification d'agglutinats |
| JPH01107154A (ja) * | 1987-10-20 | 1989-04-25 | Seitetsu Kagaku Co Ltd | 加工赤血球およびその製造方法 |
| US5061381A (en) * | 1990-06-04 | 1991-10-29 | Abaxis, Inc. | Apparatus and method for separating cells from biological fluids |
| GR1002306B (el) * | 1990-11-09 | 1996-05-08 | Ortho Diagnostic Systems Inc. | Αναλυση και διαταξη συγκολλησεως στηλης. |
| JPH05215750A (ja) * | 1992-02-06 | 1993-08-24 | Idemitsu Petrochem Co Ltd | 免疫学的分析方法 |
| ES2106341T3 (es) * | 1992-05-01 | 1997-11-01 | Univ Pennsylvania | Estructuras de deteccion microfabricadas. |
| US6143510A (en) * | 1994-07-29 | 2000-11-07 | Iatron Laboratories Inc. | Measuring method using whole blood sample |
| GB9418981D0 (en) * | 1994-09-21 | 1994-11-09 | Univ Glasgow | Apparatus and method for carrying out analysis of samples |
| WO1997021090A1 (fr) * | 1995-12-05 | 1997-06-12 | Gamera Bioscience | Dispositifs et procedes d'utilisation de l'acceleration centripete pour commander le deplacement de liquides dans le traitement de laboratoire automatise |
| CA2282307A1 (fr) * | 1997-02-28 | 1998-09-03 | Jorma Virtanen | Laboratoire sur disque |
| US6965433B2 (en) * | 2000-11-16 | 2005-11-15 | Nagaoka & Co., Ltd. | Optical biodiscs with reflective layers |
| WO2002044695A1 (fr) * | 2000-11-16 | 2002-06-06 | Burstein Technologies, Inc. | Methodes et appareils destines a la detection et au denombrement de lymphocytes utilisant des biodisques optiques |
| EP1410042A1 (fr) * | 2000-11-17 | 2004-04-21 | Burstein Technologies, Inc. | Procedes et appareil de determination de groupes sanguins a l'aide de disques biologiques optiques |
| EP1410045A2 (fr) * | 2000-11-22 | 2004-04-21 | Burstein Technologies, Inc. | Appareil et procedes permettant de separer des agglutinants et des particules dispersees |
-
2002
- 2002-11-15 AU AU2002362005A patent/AU2002362005A1/en not_active Abandoned
- 2002-11-15 CA CA002467740A patent/CA2467740A1/fr not_active Abandoned
- 2002-11-15 JP JP2003545095A patent/JP2005509865A/ja active Pending
- 2002-11-15 EP EP02797129A patent/EP1451589A4/fr not_active Withdrawn
- 2002-11-15 WO PCT/US2002/036792 patent/WO2003043403A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1451589A4 (fr) | 2006-07-19 |
| WO2003043403A3 (fr) | 2004-02-26 |
| EP1451589A2 (fr) | 2004-09-01 |
| JP2005509865A (ja) | 2005-04-14 |
| WO2003043403A2 (fr) | 2003-05-30 |
| CA2467740A1 (fr) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7026131B2 (en) | Methods and apparatus for blood typing with optical bio-discs | |
| US7087203B2 (en) | Methods and apparatus for blood typing with optical bio-disc | |
| JP2854058B2 (ja) | アッセイを実施するための方法及び装置 | |
| US6656430B2 (en) | Affinity binding-based system for detecting particulates in a fluid | |
| NL1003570C2 (nl) | Methode voor antigeen- en antistofbepaling in de bloedgroepserologie. | |
| AU2002362005A1 (en) | Methods and apparatus for blood typing with optical bio-discs | |
| US20020196435A1 (en) | Apparatus and methods for separating agglutinants and disperse particles | |
| US20020076354A1 (en) | Apparatus and methods for separating components of particulate suspension | |
| Bromilow et al. | Evaluation of the ID‐gel test for antibody screening and identification | |
| EP2788774B1 (fr) | Procédé et dispositif pour analyser l'antigène présent sur des érythrocytes ou un anticorps se liant à un antigène présent sur des érythrocytes | |
| US7824873B2 (en) | Blood test kit | |
| TW200523545A (en) | Optical bio-discs including spiral fluidic circuits for performing assays | |
| Rumsey et al. | New protocols in serologic testing: a review of techniques to meet today's challenges | |
| US20180059103A1 (en) | Devices and methods for detection of biomarkers | |
| ES2545879T3 (es) | Dispositivo y procedimiento de identificación y de determinación de grupos sanguíneos | |
| US20020025583A1 (en) | Analytical rotor and method for detecting analytes in liquid samples | |
| US8691160B2 (en) | Sample analysis disc and method of producing sample analysis disc | |
| JP5939021B2 (ja) | 試料分析用ディスク | |
| JP2006292410A (ja) | 分析装置およびそれに使用する分析デバイス | |
| Sigdel et al. | Comparison between the manual method of indirect Coombs via gel technology and solid phase red cell adherence | |
| WO2002059622A1 (fr) | Procedes et appareil de determination de groupes sanguins a l'aide de disques biologiques optiques | |
| EP2340123B1 (fr) | Cuve de réaction apte à détecter des agglutinats érythrocytaires chargées d'anticorps, procédé pour la détection des agglutinats érythrocytaires chargées d'anticorps et coffret d'éléments | |
| JP6955261B2 (ja) | マイクロアレイ、マイクロアレイの製造方法、検査方法、及び検査キット | |
| WO1987006345A1 (fr) | Immuno-annalyse de mesure colorimetrique de proportionnalite | |
| CA2365178A1 (fr) | Methode et appareil de determination du groupe sanguin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NAGAOKA & CO., LTD.; BURSTEIN TECHNOLOGIES, INC. Free format text: FORMER APPLICANT(S): BURSTEIN TECHNOLOGIES, INC. |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |